Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Declines By 53.5%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totaling 8,093 shares, a decline of 53.5% from the July 15th total of 17,399 shares. Based on an average trading volume of 14,409 shares, the short-interest ratio is presently 0.6 days. Approximately 0.6% of the company’s stock are sold short.

Hedge Funds Weigh In On Global X Genomics & Biotechnology ETF

Institutional investors have recently modified their holdings of the company. Smartleaf Asset Management LLC grew its position in Global X Genomics & Biotechnology ETF by 30.9% in the 2nd quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock valued at $164,000 after purchasing an additional 4,615 shares during the period. Sei Investments Co. increased its position in shares of Global X Genomics & Biotechnology ETF by 110.4% during the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after acquiring an additional 12,105 shares in the last quarter. C M Bidwell & Associates Ltd. acquired a new stake in shares of Global X Genomics & Biotechnology ETF in the 2nd quarter worth about $242,000. Wealth Management Partners LLC bought a new position in Global X Genomics & Biotechnology ETF in the 1st quarter valued at about $244,000. Finally, Creative Financial Designs Inc. ADV boosted its stake in Global X Genomics & Biotechnology ETF by 4.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 12,124 shares of the company’s stock valued at $551,000 after purchasing an additional 481 shares during the last quarter. 56.95% of the stock is owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Stock Down 1.2%

NASDAQ:GNOM traded down $0.70 during trading hours on Friday, reaching $58.36. The company had a trading volume of 11,784 shares, compared to its average volume of 15,683. Global X Genomics & Biotechnology ETF has a twelve month low of $36.00 and a twelve month high of $59.99. The firm has a market cap of $85.21 million, a price-to-earnings ratio of -24.94 and a beta of 1.17. The business’s 50-day simple moving average is $54.86 and its two-hundred day simple moving average is $49.06.

Global X Genomics & Biotechnology ETF Announces Dividend

The company also recently announced a dividend, which was paid on Tuesday, July 7th. Investors of record on Monday, June 29th were given a $0.0579 dividend. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s payout ratio is presently -27.35%.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.